UK Markets open in 2 hrs 28 mins

JNJ Jan 2022 110.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
39.900.00 (0.00%)
As of 3:42PM EDT. Market open.
Full screen
Previous close39.90
Open39.90
Bid0.00
Ask0.00
Strike110.00
Expiry date2022-01-21
Day's range39.90 - 39.90
Contract rangeN/A
Volume5
Open interestN/A
  • Coronavirus update: Russia approves world's first vaccine amid skepticism, Trump weighs travel ban on Americans
    Editor's pick
    Yahoo Finance

    Coronavirus update: Russia approves world's first vaccine amid skepticism, Trump weighs travel ban on Americans

    Latest news and updates and the global coronavirus pandemic.

  • Mexico to trial China, U.S. COVID-19 vaccines, may produce some
    Reuters

    Mexico to trial China, U.S. COVID-19 vaccines, may produce some

    Mexico aims to conduct late-stage clinical trials for COVID-19 vaccines in development by U.S. and Chinese companies, two of which might base some of their vaccine production in the country, the foreign ministry said on Tuesday. Mexico has signed memorandums of understanding with Johnson & Johnson, along with Chinese companies CanSino Biologics Inc and Walvax Biotechnology Co Ltd, Foreign Minister Marcelo Ebrard said at a news conference.

  • J&J eyes 1 billion doses of potential COVID-19 shot in 2021, weighs challenge trials
    Reuters

    J&J eyes 1 billion doses of potential COVID-19 shot in 2021, weighs challenge trials

    Johnson & Johnson could produce 1 billion doses of its potential COVID-19 vaccine next year if it proves successful and would consider injecting healthy volunteers with the novel coronavirus if there are not enough patients for final trials, a company executive said. J&J kicked off in July early-stage human safety trials for its potential COVID-19 vaccine after releasing details of a study in monkeys that showed its best-performing candidate offered strong protection in a single dose. Large-scale trials are set to start by the beginning of October and J&J aims to have results on the vaccine's efficacy between the end of this year and mid-2021, Johan Van Hoof, head of vaccines at Janssen, told Reuters on Tuesday in a telephone interview.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more